Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

4D pharma PLC Sponsored ADR LBPS

Healthcare  —  Biotechnology
Market cap
$37.2M
P/E
0.0×
Revenue Champion (5y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

4D pharma PLC Sponsored ADR (LBPS) Business Profile

Updated before January 2025

Company Overview

4D pharma PLC Sponsored ADR (LBPS) is a pioneering biotechnology company specializing in the development of live biotherapeutics. Founded in 2014, the company is headquartered in Leeds, United Kingdom. 4D pharma is a global leader in the emerging field of microbiome-based therapeutics, leveraging the human microbiome to develop innovative treatments for a range of diseases. The company was co-founded by Duncan Peyton and Alex Stevenson, who envisioned harnessing the power of the microbiome to revolutionize medicine. The leadership team includes Duncan Peyton as CEO and Alex Stevenson as Chief Scientific Officer, both of whom bring extensive experience in the pharmaceutical and biotechnology sectors.

Core Business Segments

4D pharma focuses on the development and commercialization of live biotherapeutics, which are a novel class of medicines derived from the human microbiome. The company’s core business segments include:

Gastrointestinal Disorders

4D pharma has developed live biotherapeutics targeting gastrointestinal diseases such as irritable bowel syndrome (IBS) and Crohn’s disease. Key products include Blautix, which is designed to treat IBS by modulating the gut microbiome.

Oncology

The company is at the forefront of using live biotherapeutics to enhance cancer immunotherapy. MRx0518, one of its flagship products, is being developed as an immuno-oncology therapy to improve the efficacy of immune checkpoint inhibitors.

Respiratory Diseases

4D pharma is also exploring the potential of live biotherapeutics in treating respiratory conditions such as asthma. The company’s research in this area is focused on modulating the microbiome to reduce inflammation and improve respiratory health.

Central Nervous System (CNS) Disorders

The company is investigating the gut-brain axis and its role in CNS disorders such as Parkinson’s disease. MRx0029 is one of the key candidates in this segment, aimed at addressing neurodegenerative diseases.

Business Model

4D pharma’s business model is centered around the discovery, development, and commercialization of live biotherapeutics. The company employs a proprietary platform called MicroRx®, which enables the identification and development of specific bacterial strains with therapeutic potential. Revenue is generated through partnerships, licensing agreements, and the eventual commercialization of its products. The company also collaborates with leading pharmaceutical companies to co-develop therapies, thereby expanding its market reach and accelerating product development.

Strategic Direction

4D pharma is committed to advancing the field of live biotherapeutics and expanding its product pipeline. The company’s strategic priorities include:

  • Pipeline Expansion: Developing new live biotherapeutics for a broader range of diseases, including autoimmune disorders and metabolic diseases.
  • Global Partnerships: Strengthening collaborations with pharmaceutical companies to co-develop and commercialize products.
  • Regulatory Approvals: Securing regulatory approvals for its lead candidates, such as MRx0518 and Blautix, to bring them to market.
  • Sustainability Goals: Incorporating sustainable practices in its research and manufacturing processes to minimize environmental impact.

Competitive Landscape

4D pharma operates in a highly competitive biotechnology sector, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Seres Therapeutics: A leader in microbiome-based therapeutics with a focus on infectious diseases and gastrointestinal disorders.
  • Vedanta Biosciences: Specializes in developing microbiome-derived therapies for autoimmune and inflammatory diseases.
  • Rebiotix (a Ferring Pharmaceuticals company): Focused on microbiome-based treatments for recurrent Clostridium difficile infections.

Despite the competition, 4D pharma differentiates itself through its proprietary MicroRx® platform and its focus on live biotherapeutics.

Risk Factors

4D pharma faces several risks that could impact its business operations and financial performance:

  • Regulatory Challenges: The approval process for live biotherapeutics is complex and may face delays or rejections.
  • Market Dependence: The company’s success is heavily reliant on the commercialization of its lead candidates.
  • Supply Chain Disruptions: Dependence on specialized manufacturing processes and suppliers could lead to delays in production.
  • Financial Risks: As a clinical-stage company, 4D pharma relies on external funding and may face challenges in securing additional capital.

Recent Developments

4D pharma has made significant progress in advancing its pipeline and corporate strategy:

  • Clinical Trials: The company recently announced positive interim results from its Phase I/II clinical trial of MRx0518 in combination with immune checkpoint inhibitors for cancer treatment.
  • Partnerships: 4D pharma entered into a collaboration with Merck & Co. to evaluate the combination of MRx0518 with Merck’s Keytruda®.
  • Innovation: The company continues to leverage its MicroRx® platform to identify new therapeutic candidates.
  • Global Developments: The COVID-19 pandemic highlighted the importance of microbiome research, leading to increased interest and investment in the field.

Investment Considerations

Investors considering 4D pharma should weigh the following strengths and risks:

Strengths

  • Innovative Technology: Proprietary MicroRx® platform provides a competitive edge.
  • Diverse Pipeline: Broad range of therapeutic candidates targeting multiple disease areas.
  • Strategic Partnerships: Collaborations with leading pharmaceutical companies enhance credibility and market reach.

Risks

  • Clinical and Regulatory Uncertainty: Success depends on the outcome of clinical trials and regulatory approvals.
  • Financial Dependence: Reliance on external funding poses financial risks.
  • Market Competition: Intense competition in the biotechnology sector could impact market share.

Conclusion

4D pharma PLC Sponsored ADR (LBPS) is a trailblazer in the field of live biotherapeutics, leveraging the human microbiome to develop innovative treatments for a wide range of diseases. With a robust pipeline, strategic partnerships, and a proprietary technology platform, the company is well-positioned for growth. However, investors should consider the inherent risks associated with clinical-stage biotechnology companies. Overall, 4D pharma’s pioneering approach and commitment to innovation make it a compelling player in the biotechnology sector.